-

02:57:24 PM

VERU Stock News

VERU - Veru Inc

09/21/22 8:30 AM

Nasdaq : VERU

conferences

Veru to Participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28th, 2022

Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Company will participate in

RHEA-AI

neutral

09/19/22 12:15 PM

Nasdaq : VERU

covid-19

Veru Announces FDA has Updated the Meeting Date for the Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the

RHEA-AI

neutral

09/07/22 1:45 PM

Nasdaq : VERU

covid-19

Veru Announces Date for FDA Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate

RHEA-AI

neutral

09/06/22 8:30 AM

Nasdaq : VERU

conferences

Veru to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12th, 2022

Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Company will present at the

RHEA-AI

neutral

08/22/22 8:30 AM

Nasdaq : VERU

covid-19

Veru Granted Expedited Provisional Registration Regulatory Pathway for Sabizabulin Treatment in Hospitalized COVID-19 Patients by Australia's Therapeutic Goods Administration

Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that Australia's Therapeutic Goods

RHEA-AI

neutral

08/19/22 8:30 AM

Nasdaq : VERU

managementcovid-19

Veru Announces Appointment of Jason Davies to Lead EMEA, LATAM and APAC Infectious Disease Franchise for Veru International Focused on Hospitalized COVID-19 Patients

Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced the appointment of Jason Davies as

RHEA-AI

neutral

08/12/22 4:30 PM

Nasdaq : VERU

Veru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced the granting of inducement awards to

RHEA-AI

neutral

08/11/22 6:30 AM

Nasdaq : VERU

earningscovid-19

Veru Reports Third Quarter Fiscal 2022 Financial Results; Progresses Sabizabulin Treatment for COVID-19 Towards Regulatory Decisions in Key Territories

European Medicines

RHEA-AI

neutral

08/09/22 8:30 AM

Nasdaq : VERU

clinical trialcovid-19

Veru Announces Presentation of Phase 3 Study of Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 11th International Conference on Emerging Infectious Diseases (ICEID) on August 7-10, 2022

Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Phase 3 COVID-19 study

RHEA-AI

neutral

07/28/22 8:30 AM

Nasdaq : VERU

conferencesearnings

Veru to Report Fiscal 2022 Third Quarter Financial Results, Host Conference Call on August 11th

Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that it will report financial results

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

VERU Data

IndustryPharmaceutical Preparation Manufacturing
Websiteverupharma.com
CeoMitchell Steiner
Security nameVeru Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees339
Tags
- Consumer Non-Durables
- Household/Personal Care
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address48 NW 25th St Ste 102
StateFlorida
CityMiami
Zip33127-4442
CountryUnited States
Phone13125959123

About Veru Inc

Veru Inc. is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer. The Veru prostate cancer pipeline includes VERU-111, VERU-100, and Zuclomiphene citrate. VERU-111 is an oral, first-in-class, new chemical entity that targets, crosslinks, and disrupts alpha and beta tubulin subunits of microtubules for the treatment of metastatic castration and androgen receptor resistant prostate cancer. VERU-100 is a novel, proprietary peptide formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer. Zuclomiphene citrate is an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT in men with advanced prostate cancer. The Veru breast cancer pipeline includes enobosarm for AR+/ER+/HER2- metastatic breast cancer and VERU-111 for taxane resistant metastatic triple negative breast cancer. Enobosarm is an oral, first-in-class, new chemical entity, selective androgen receptor agonist that targets and activates the androgen receptor in AR+/ER+/HER2- metastatic breast cancer without unwanted masculinizing side effects. VERU-111 is also being advanced into a Phase 3 trial for the treatment of hospitalized patients with COVID-19 who are at high risk for acute respiratory distress syndrome.